Prosecution Insights
Last updated: November 20, 2026
Application No. 18/354,302

COMPOSITIONS AND RELATED METHODS

Final Rejection §102§103
Filed
Jul 18, 2023
Priority
Aug 17, 2022 — CN 202210985240.6
Examiner
WEBB, WALTER E
Art Unit
1612
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Colgate-Palmolive Company
OA Round
2 (Final)
46%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
465 granted / 1007 resolved
-13.8% vs TC avg
Strong +19% interview lift
Without
With
+18.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
59 currently pending
Career history
1068
Total Applications
across all art units

Statute-Specific Performance

§101
0.8%
-39.2% vs TC avg
§103
52.2%
+12.2% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
16.3%
-23.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1007 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Applicants' arguments, filed 09/30/2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 102/103 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-12 is/are rejected under 35 U.S.C. 102(a)(1) as anticipated by or, in the alternative, under 35 U.S.C. 103 as obvious over Yuan et al., (US 2018/0133129). Yuan et al. teaches oral care compositions comprising “from about 0.01% to about 40% peroxysulfate whitening agent and from about 1% to about 99% non-aqueous dispersant” (Abstract). Yuan et al. teaches a specific embodiment below: PNG media_image1.png 450 604 media_image1.png Greyscale (see p. 7, para. [0086]). Here, the embodiment includes 1% (0.5% MPS) Oxone, which is a triple salt of potassium peroxymonosulfate, as per claims 1-4. It is the only oxidizing agent, as per claim 5, and further includes 23% polyvinyl pyrrolidone, as the water-soluble polymer, as per claim 6, 10% PEG-600 (polyethylene glycol (dispersant; humectant), as per claims 7-10. The embodiment further comprises a thickening agent, which includes polysaccharides, i.e. “carrageenan” (p. 5, para. [0070]), as per claim 11; and a pH modifying agent, which is taught to modify the pH within the range of “about 5 to about 7” (p. 6, para. [0076]), which falls within the pH range recited in claim 12 This embodiment was taught to be in the form of a slurry insofar as Yaun et al. teaches, “Two slurries were used to brush the bovine incisors for 2 minutes under a 250 g force. One slurry contained 2 g of oral composition #1 and 2 g of artificial saliva” (p. 6, para. [0098]). Since artificial saliva is primarily water (>90%; see Technoloogical Background), the slurry is reasonably expected to have greater than 30% water (2g artificial saliva is roughly half the weight of the slurry). Note: Yuan also teaches that the compositions are activated by water (p. 2, para. [0023]; p. 3, [0052] teaching, “the oral composition is activated when exposed to water outside the oral cavity”), as per McLaughlin (above). The prior art is anticipatory insofar as it teaches an aqueous slurry of 0.01% to 5% MPS, greater than 30% water, 10% to 40% PVP, 0.5 to 10% humectant, i.e. polyethylene glycol 600. Claim Rejections - 35 USC § 103—Previous The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 13-15 are rejected under 35 U.S.C. 103 as being unpatentable over Yuan et al., (US 2018/0133129), as applied to claims 1-12 above. Yuan et al. which is taught above, differs from claims 13-15 insofar as the formulations are not taught to “consist” of the ingredients recited therein or 60 to 80% water. As taught above, the formulations of Yuan include Oxone, which is a triple salt of peroxymonosulfate, PVP, and PEG 600. The compositions are also taught to be pH adjusted insofar as Yuan teaches, “MPS is more stable either as a solid or in an non-aqueous formulation, and it is most active as an oxidizing agent (and tooth whitening agent) in an aqueous solution at pH 5-8” (p. 3, para. [0051]). Yuan uses water to activate the formulations (see p. 3, [0052] teaching, “the oral composition is activated when exposed to water outside the oral cavity”). pH modifying agents are specifically taught at p. 6, para. [0076]. Since the compositions of Yuan only require peroxysulfate (e.g. MPS, Oxone) and a nonaqueous dispersant (see abstract), it would have been obvious to a person having ordinary skill in the art at the time of applicant’s filing to provide formulations that consist of MPS (Oxone), water (activating agent), PVP, PEG 600, and pH adjusting agent, as per claims 13-14. Concerning the amount of water, water is taught therein as an activating agent, as well as a dispersant in making a slurry. Again, 2g of oral care composition #1 was combined with 2g artificial saliva to form a slurry. The amount of water here (from the artificial saliva) is reasonably expected to be greater than 30%; however, it is unclear what amount is sufficient to provide a slurry. Given that the function of the slurry was to demonstrate whitening efficacy on teeth, it would have been obvious to optimize a range of water for the slurry. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation" (see MPEP 2144.05 IIA quoting In re Aller, 220 F.2d 454, 456 (105 USPQ 233)). The adjustment of particular conventional working conditions of water (e.g., determining result effective amounts of the ingredients beneficially taught by the cited references, especially within the broad ranges instantly claimed), is deemed merely a matter of judicious selection and routine optimization which is well within the purview of the skilled artisan. Accordingly, this type of modification would have been well within the purview of the skilled artisan and no more than an effort to optimize results. Technological Background The prior art made of record and considered pertinent to applicant's disclosure Saito et al, (EP 0596675). Saito et al. is pertinent for teaching, “Artificial saliva compositions which contain lysozyme chloride in concentrations of 0.2 to 0.6 % (w/v) effectively surpass the development of oral edema and possess improved feeling of use and show lessened change in appearance and pH value as well as minimized reduction in enzymatic activity of lysozyme chloride after prolonged use” (Abstract). Saito et al. teaches a specific embodiment of an artificial saliva comprising water Q.S. ~97% below: PNG media_image2.png 608 1073 media_image2.png Greyscale (p. 3). Response to Arguments i) Applicant argues, that the Yuan fails to teach the inventive claims as amended. Noting that Yuan teaches uses with devices other than a whitening strip, e.g., felt tip, and could not have greater than 30% water in its compositions, as claimed, insofar as the compositions of Yuan are taught to be nonaqueous. Applicant further adds that the compositions of Yuan are taught to be substantially free of liquid ingredients with a high density of hydroxyl groups (p. 10). However, the instant claims have been amended such that the composition is in the form of a slurry, which would have been obvious insofar as Yan teaches using water to activate the formulations, “the oral composition is activated when exposed to water outside the oral cavity” (p. 2, para. [0023]). Given the need of water for activation, it would have been obvious for the person having ordinary skill in the art to optimize a range for water. Moreover, Yuan et al. teaches making a slurry of the inventive formulation, i.e., Oral Care Composition #1, wherein half of the slurry, i.e., 2g, was artificial saliva, which is greater than 90% water. Note: Natural saliva is about 98% to 99.5% water. The artisan would have reasonably expected the slurry to comprise greater than 30% water, as a result of mixing 2g Oral Care Composition #1 with 2g artificial saliva. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to WALTER E WEBB whose telephone number is (571)270-3287 and fax number is (571) 270-4287. The examiner can normally be reached from Mon-Fri 7-3:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Sahana Kaup can be reached (571) 272-6897. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Walter E. Webb /WALTER E WEBB/Primary Examiner, Art Unit 1612
Read full office action

Prosecution Timeline

Jul 18, 2023
Application Filed
Jun 30, 2026
Non-Final Rejection mailed — §102, §103
Sep 30, 2026
Response Filed
Nov 10, 2026
Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797305
FLUORIDE COMPOSITION AND METHODS FOR DENTAL MINERALIZATION
4y 0m to grant Granted Nov 17, 2026
Patent 12778860
Delivery Carrier For Tooth Whitening
4y 11m to grant Granted Nov 03, 2026
Patent 12778874
Catalase Composition with Improved Stability and Methods
4y 1m to grant Granted Nov 03, 2026
Patent 12773379
METHODS OF USE OF ORAL CARE COMPOSITIONS COMPRISING HOPS
2y 5m to grant Granted Oct 27, 2026
Patent 12758476
ACID RESISTANT COMPOSITION HAVING IMPROVED SOLUBILITY
4y 4m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
46%
Grant Probability
65%
With Interview (+18.9%)
3y 4m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1007 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month